Skip to main content
Erschienen in: Inflammation 6/2023

02.11.2023 | RESEARCH

Evaluation of Serum Paraoxonase, Myeloperoxidase, and HDL-Cholesterol Levels in Acute Myeloid Leukemia

verfasst von: Suat Sincan, Gülden Sincan, Seda Aşkın, Ahmet Kızıltunç

Erschienen in: Inflammation | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Inflammation and oxidative stress play a significant role in the pathogenesis of acute myeloid leukemia. While myeloperoxidase carries pro-oxidant effects, HDL-cholesterol and paraoxonase have antioxidant properties. Therefore, we evaluated serum paraoxonase, myeloperoxidase, and HDL-cholesterol levels in cases with acute myeloid leukemia. Myeloperoxidase, paraoxonase, and HDL-cholesterol levels in 40 acute myeloid leukemia patients and 18 healthy individuals were determined. The relationship between these parameters and other prognostic factors, as well as their association with response to chemotherapy, was investigated. Myeloperoxidase levels were higher, while paraoxonase and HDL-cholesterol levels were lower in acute myeloid leukemia cases compared to the control group (p < 0.001, p < 0.001, p = 0.006, respectively). The myeloperoxidase level was significantly negatively correlated with paraoxonase and HDL-c levels (r =  − 0.64, p < 0.001; r =  − 0.27, p = 0.02, respectively). Paraoxonase level was positively correlated with HDL level (r = 0.34, p = 0.04). Lactate dehydrogenase level was negatively correlated with HDL-c and paraoxonase levels and positively correlated with myeloperoxidase level (r =  − 0.37, p = 0.019; r =  − 0.35, p = 0.04; r = 0.45, p = 0.03, respectively). Following complete remission induction treatment, cases with complete remission had lower myeloperoxidase levels and higher HDL-cholesterol and paraoxonase levels compared to other cases (p = 0.03, p = 0.01, p = 0.04, respectively). Myeloperoxidase levels are higher, while paraoxonase and HDL-cholesterol levels are lower in acute myeloid leukemia cases. The obtained findings emphasize the potential importance of inflammation and oxidative stress in the pathogenesis of acute myeloid leukemia. These parameters can be used as biomarkers for prognosis prediction and prediction of response to chemotherapy.
Literatur
1.
Zurück zum Zitat Prieto-Bermejo, R., M. Romo-González, A. Pérez-Fernández, C. Ijurko, and A. Hernández-Hernández. 2018. Reactive oxygen species in haematopoiesis: Leukaemic cells take a walk on the wild side. Journal of Experimental & Clinical Cancer Research 37 (1): 125–142.CrossRef Prieto-Bermejo, R., M. Romo-González, A. Pérez-Fernández, C. Ijurko, and A. Hernández-Hernández. 2018. Reactive oxygen species in haematopoiesis: Leukaemic cells take a walk on the wild side. Journal of Experimental & Clinical Cancer Research 37 (1): 125–142.CrossRef
2.
Zurück zum Zitat Trachootham, D., J. Alexandre, and P. Huang. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nature Reviews. Drug Discovery 8 (7): 579–591.CrossRefPubMed Trachootham, D., J. Alexandre, and P. Huang. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nature Reviews. Drug Discovery 8 (7): 579–591.CrossRefPubMed
3.
Zurück zum Zitat Singh, N., D. Baby, J.P. Rajguru, P.B. Patil, S.S. Thakkannavar, V.B. Pujari VB. 2019. Inflammation and cancer. Annals of African Medicine 18 (3): 121–126. Singh, N., D. Baby, J.P. Rajguru, P.B. Patil, S.S. Thakkannavar, V.B. Pujari VB. 2019. Inflammation and cancer. Annals of African Medicine 18 (3): 121–126.
4.
Zurück zum Zitat Rybicka-Ramos, M., M. Markiewicz, A. Suszka-Switek, R. Wiaderkiewicz, S. Mizia, M. Dzierzak-Mietla, and K. Bialas. 2021. Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation. Am J Blood Res. 11 (2): 149–156.PubMedPubMedCentral Rybicka-Ramos, M., M. Markiewicz, A. Suszka-Switek, R. Wiaderkiewicz, S. Mizia, M. Dzierzak-Mietla, and K. Bialas. 2021. Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation. Am J Blood Res. 11 (2): 149–156.PubMedPubMedCentral
5.
Zurück zum Zitat Blatter, MC., R.W. James, S. Messmer, F. Barja, D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. European Journal of Biochemistry 211 (3): 871–879. Blatter, MC., R.W. James, S. Messmer, F. Barja, D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. European Journal of Biochemistry 211 (3): 871–879.
6.
Zurück zum Zitat Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R.W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. Journal of Biological Chemistry 277 (6): 4301–4308.CrossRefPubMed Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R.W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. Journal of Biological Chemistry 277 (6): 4301–4308.CrossRefPubMed
7.
Zurück zum Zitat Wang, Y., J. Zhang, Y. Hu, L. Yang, J. Xue, and Y. Ding. 2019. Relationship between paraoxonase-1 activity and lipid profiles in Chinese individuals with or without coronary artery disease. Lipids in Health and Disease. 18 (1): 45. Wang, Y., J. Zhang, Y. Hu, L. Yang, J. Xue, and Y. Ding. 2019. Relationship between paraoxonase-1 activity and lipid profiles in Chinese individuals with or without coronary artery disease. Lipids in Health and Disease. 18 (1): 45.
8.
Zurück zum Zitat Mackness, MI., B. Mackness, P.N. Durrington, P.W. Connelly, R.A. Hegele. 1996. Paraoxonase: Biochemistry, genetics, and relationship to plasma lipoproteins. Current Opinion in Lipidology 7: 69–76. Mackness, MI., B. Mackness, P.N. Durrington, P.W. Connelly, R.A. Hegele. 1996. Paraoxonase: Biochemistry, genetics, and relationship to plasma lipoproteins. Current Opinion in Lipidology 7: 69–76.
9.
Zurück zum Zitat Nevin, DN., A. Zambon, C.E. Furlong, R.J. Richter, R. Humbert, J.E. Hokanson, J.D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 1243–1249. Nevin, DN., A. Zambon, C.E. Furlong, R.J. Richter, R. Humbert, J.E. Hokanson, J.D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 1243–1249.
10.
Zurück zum Zitat Costa, LG., A. Vitalone, T.B. Cole, C.E. Furlong. 2005. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology 69: 541–550. Costa, LG., A. Vitalone, T.B. Cole, C.E. Furlong. 2005. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology 69: 541–550.
11.
Zurück zum Zitat Baum, L., H.K. Ng, K.S. Woo, B. Tomlinson, T.H. Rainer, X. Chen, W.S. Cheung, D.K. Chan, G.N. Thomas, C.S. Tong, and K.S. Wong. 2006. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clinical Biochemistry 39: 191–195.CrossRefPubMed Baum, L., H.K. Ng, K.S. Woo, B. Tomlinson, T.H. Rainer, X. Chen, W.S. Cheung, D.K. Chan, G.N. Thomas, C.S. Tong, and K.S. Wong. 2006. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clinical Biochemistry 39: 191–195.CrossRefPubMed
12.
Zurück zum Zitat Gokdemir, MT., A.Z. Karakilcik, G.S. Gokdemir. 2017. Prognostic importance of paraoxonase, arylesterase and mean platelet volume efficiency in acute ischaemic stroke. Journal of Pakistan Medical Association 67: 1679–1683. Gokdemir, MT., A.Z. Karakilcik, G.S. Gokdemir. 2017. Prognostic importance of paraoxonase, arylesterase and mean platelet volume efficiency in acute ischaemic stroke. Journal of Pakistan Medical Association 67: 1679–1683.
13.
Zurück zum Zitat Utanğaç, MM., E. Yeni, M. Savaş, A. Altunkol, H. Çiftçi, K. Gümüş, M. Demir. 2017. Paraoxonase and arylesterase activity in bladder cancer. Turkish Journal of Urology 43: 147–51. Utanğaç, MM., E. Yeni, M. Savaş, A. Altunkol, H. Çiftçi, K. Gümüş, M. Demir. 2017. Paraoxonase and arylesterase activity in bladder cancer. Turkish Journal of Urology 43: 147–51.
14.
Zurück zum Zitat Kul, A., H. Uzkeser, and N. Ozturk. 2017. Paraoxonase and arylesterase levels in Behcet’s disease and their relations with the disease activity. Biochemical Genetics 55: 335–344.CrossRefPubMed Kul, A., H. Uzkeser, and N. Ozturk. 2017. Paraoxonase and arylesterase levels in Behcet’s disease and their relations with the disease activity. Biochemical Genetics 55: 335–344.CrossRefPubMed
15.
Zurück zum Zitat Khan, AA., M.A. Alsahli, A.H. Rahmani. 2018. Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives. Medical Sciences (Basel) 6 (2): 33. Khan, AA., M.A. Alsahli, A.H. Rahmani. 2018. Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives. Medical Sciences (Basel) 6 (2): 33.
16.
Zurück zum Zitat Anatoliotakis, N., S. Deftereos, G. Bouras, G. Giannopoulos, D. Tsounis, C. Angelidis, A. Kaoukis, and C. Stefanadis. 2013. Myeloperoxidase: Expressing inflammation and oxidative stress in cardiovascular disease. Current Topics in Medicinal Chemistry 13 (2): 115–138.CrossRefPubMed Anatoliotakis, N., S. Deftereos, G. Bouras, G. Giannopoulos, D. Tsounis, C. Angelidis, A. Kaoukis, and C. Stefanadis. 2013. Myeloperoxidase: Expressing inflammation and oxidative stress in cardiovascular disease. Current Topics in Medicinal Chemistry 13 (2): 115–138.CrossRefPubMed
17.
Zurück zum Zitat Ajila, V., V. Ravi, S. Kumari, S. Babu, S. Hegde, and A. Madiyal. 2015. Serum and salivary myeloperoxidase in oral squamous cell carcinoma: A preliminary study. Clin Cancer Investig J. 4 (3): 344–348. Ajila, V., V. Ravi, S. Kumari, S. Babu, S. Hegde, and A. Madiyal. 2015. Serum and salivary myeloperoxidase in oral squamous cell carcinoma: A preliminary study. Clin Cancer Investig J. 4 (3): 344–348.
18.
Zurück zum Zitat Lai, WM., C.C. Chen, J.H. Lee, C.J. Chen, J.S. Wang, Y.Y. Hou, H.H. Liou, H.C. Chen, T.Y. Fu, Y.C. Lee, L.P. Ger. 2013. Second primary tumors and myeloperoxidase expression in buccal mucosal squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 116 (4): 464–473. Lai, WM., C.C. Chen, J.H. Lee, C.J. Chen, J.S. Wang, Y.Y. Hou, H.H. Liou, H.C. Chen, T.Y. Fu, Y.C. Lee, L.P. Ger. 2013. Second primary tumors and myeloperoxidase expression in buccal mucosal squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 116 (4): 464–473.
19.
Zurück zum Zitat Qin, X., Y. Deng, Z.Y. Zeng, Q.L. Peng, X.L. Huang, C.J. Mo, S. Li, and J.M. Zhao. 2013. Myeloperoxidase polymorphism, menopausal status, and breast cancer risk: An update meta-analysis. PLoS ONE 8 (8): e72583.CrossRefPubMedPubMedCentral Qin, X., Y. Deng, Z.Y. Zeng, Q.L. Peng, X.L. Huang, C.J. Mo, S. Li, and J.M. Zhao. 2013. Myeloperoxidase polymorphism, menopausal status, and breast cancer risk: An update meta-analysis. PLoS ONE 8 (8): e72583.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Arslan, S., H. Pinarbasi, and Y. Silig. 2011. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Molecular Medicine Reports 4 (1): 87–92.PubMed Arslan, S., H. Pinarbasi, and Y. Silig. 2011. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Molecular Medicine Reports 4 (1): 87–92.PubMed
21.
Zurück zum Zitat Jilani, I., T. Vincenti, H. Faraji, F.J. Giles, E. Estey, H.M. Kantarjian, and M. Albitar. 2004. Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 104 (11): 1073.CrossRef Jilani, I., T. Vincenti, H. Faraji, F.J. Giles, E. Estey, H.M. Kantarjian, and M. Albitar. 2004. Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 104 (11): 1073.CrossRef
22.
Zurück zum Zitat Gonçalves, RP., D.G. Rodrigues, R.C. Maranhão. 2005. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leukemia Research 29 (8): 955–959. Gonçalves, RP., D.G. Rodrigues, R.C. Maranhão. 2005. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leukemia Research 29 (8): 955–959.
23.
Zurück zum Zitat Kuliszkiewicz-Janus, M., R. Małecki, and A.S. Mohamed. 2008. Lipid changes occuring in the course of hematological cancers. Cellular & Molecular Biology Letters 13: 465–474.CrossRef Kuliszkiewicz-Janus, M., R. Małecki, and A.S. Mohamed. 2008. Lipid changes occuring in the course of hematological cancers. Cellular & Molecular Biology Letters 13: 465–474.CrossRef
24.
Zurück zum Zitat Rye, KA., C.A. Bursill, G. Lambert, F. Tabet, P.J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research 50: 195–200. Rye, KA., C.A. Bursill, G. Lambert, F. Tabet, P.J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research 50: 195–200.
25.
Zurück zum Zitat Undurti, A., Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, and S.L. Hazen. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. Journal of Biological Chemistry 284 (45): 30825–30835.CrossRefPubMedPubMedCentral Undurti, A., Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, and S.L. Hazen. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. Journal of Biological Chemistry 284 (45): 30825–30835.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Eckerson, EW., J. Romson, C. Wyte, B.N. La Du. 1983. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. American Journal of Human Genetics 35: 214–227. Eckerson, EW., J. Romson, C. Wyte, B.N. La Du. 1983. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. American Journal of Human Genetics 35: 214–227.
27.
Zurück zum Zitat Bradly, PP., D.A. Priebat, R.D. Christensen, G. Rathstein. 1982. Measurement of cutaneous inflammations estimation of neutrophil content with an enzyme marker. Journal of Investigative Dermatology 78 (3): 206–209. Bradly, PP., D.A. Priebat, R.D. Christensen, G. Rathstein. 1982. Measurement of cutaneous inflammations estimation of neutrophil content with an enzyme marker. Journal of Investigative Dermatology 78 (3): 206–209.
28.
Zurück zum Zitat Akçay, MN., I. Yilmaz, M.F. Polat, G. Akçay. 2003. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50: cclxxiii-cclxxv. Akçay, MN., I. Yilmaz, M.F. Polat, G. Akçay. 2003. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50: cclxxiii-cclxxv.
29.
Zurück zum Zitat Elkiran, ET., N. Mar, B. Aygen, F. Gursu, A. Karaoglu, S. Koca. 2007. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 15: 48. Elkiran, ET., N. Mar, B. Aygen, F. Gursu, A. Karaoglu, S. Koca. 2007. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 15: 48.
30.
Zurück zum Zitat Samra, ZQ., S. Pervaiz, S. Shaheen, N. Dar, M.A. Athar. 2011. Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients. Clinical Laboratory 57 (9–10): 741–747. Samra, ZQ., S. Pervaiz, S. Shaheen, N. Dar, M.A. Athar. 2011. Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients. Clinical Laboratory 57 (9–10): 741–747.
31.
Zurück zum Zitat Çebi, A., E. Akgun, R. Esen, H. Demir, and A. Çifci. 2015. The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia: Preliminary results. European Review for Medical and Pharmacological Sciences 19 (23): 4590–4594.PubMed Çebi, A., E. Akgun, R. Esen, H. Demir, and A. Çifci. 2015. The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia: Preliminary results. European Review for Medical and Pharmacological Sciences 19 (23): 4590–4594.PubMed
32.
Zurück zum Zitat Bacchetti, T., G. Ferretti, and A. Sahebkar. 2019. The role of paraoxonase in cancer. Seminars in Cancer Biology 56: 72–86.CrossRefPubMed Bacchetti, T., G. Ferretti, and A. Sahebkar. 2019. The role of paraoxonase in cancer. Seminars in Cancer Biology 56: 72–86.CrossRefPubMed
33.
Zurück zum Zitat Morsia, E., S. Rupoli, E. Molinelli, D. Sartini, A.M. Ofdani, M. Emanuelli, E. Salvolini, A. Olivieri, and G. Goteri. 2021. Expression of paraoxonase-2 in different stages of cutaneous T cell lymphoma: Is it a potential biomarker for aggressiveness? Blood 138: 4496–4497.CrossRef Morsia, E., S. Rupoli, E. Molinelli, D. Sartini, A.M. Ofdani, M. Emanuelli, E. Salvolini, A. Olivieri, and G. Goteri. 2021. Expression of paraoxonase-2 in different stages of cutaneous T cell lymphoma: Is it a potential biomarker for aggressiveness? Blood 138: 4496–4497.CrossRef
34.
Zurück zum Zitat Ellidag, HY., E. Eren, O. Aydin, M. Yıldırım, C. Sezer, N. Yilmaz. 2014. Multiple myeloma: Relationship to antioxidant esterases. Medical Principles and Practice 23 (1): 18–23. Ellidag, HY., E. Eren, O. Aydin, M. Yıldırım, C. Sezer, N. Yilmaz. 2014. Multiple myeloma: Relationship to antioxidant esterases. Medical Principles and Practice 23 (1): 18–23.
35.
Zurück zum Zitat Musolino, C., L. Calabrò, G. Bellomo, M. Cincotta, V. Di Giacomo, C. Pezzano, B. Loteta, V. Rizzo, S. Guglielmo, and A. Alonci. 2002. Lipid profile in hematologic neoplasms. Rec Prog Med. 93: 298–301. Musolino, C., L. Calabrò, G. Bellomo, M. Cincotta, V. Di Giacomo, C. Pezzano, B. Loteta, V. Rizzo, S. Guglielmo, and A. Alonci. 2002. Lipid profile in hematologic neoplasms. Rec Prog Med. 93: 298–301.
36.
Zurück zum Zitat Lim, U., T. Gayles, H.A. Katki, R. Stolzenberg-Solomon, S.J. Weinstein, P. Pietinen, P.R. Taylor, J. Virtamo, and D. Albanes. 2007. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Research 67 (11): 5569–5574.CrossRefPubMed Lim, U., T. Gayles, H.A. Katki, R. Stolzenberg-Solomon, S.J. Weinstein, P. Pietinen, P.R. Taylor, J. Virtamo, and D. Albanes. 2007. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Research 67 (11): 5569–5574.CrossRefPubMed
37.
Zurück zum Zitat Fiorenza, AM., A. Branchi, D. Sommariva. 2000. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. International Journal of Clinical and Laboratory Research 30 (3): 141–145. Fiorenza, AM., A. Branchi, D. Sommariva. 2000. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. International Journal of Clinical and Laboratory Research 30 (3): 141–145.
38.
Zurück zum Zitat Baroni, S., D. Scribano, C. Zuppi, L. Pagano, G. Leone, and B. Giardina. 1996. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematologica 96 (1): 24–28.CrossRefPubMed Baroni, S., D. Scribano, C. Zuppi, L. Pagano, G. Leone, and B. Giardina. 1996. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematologica 96 (1): 24–28.CrossRefPubMed
39.
Zurück zum Zitat Wang, L., P.D. Chi, H. Chen, J. Xiang, Z.J. Xia, and Y.J. Zhang. 2014. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour Biology 35 (3): 2141–2149.CrossRefPubMed Wang, L., P.D. Chi, H. Chen, J. Xiang, Z.J. Xia, and Y.J. Zhang. 2014. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour Biology 35 (3): 2141–2149.CrossRefPubMed
Metadaten
Titel
Evaluation of Serum Paraoxonase, Myeloperoxidase, and HDL-Cholesterol Levels in Acute Myeloid Leukemia
verfasst von
Suat Sincan
Gülden Sincan
Seda Aşkın
Ahmet Kızıltunç
Publikationsdatum
02.11.2023
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01924-0

Weitere Artikel der Ausgabe 6/2023

Inflammation 6/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.